Both the anti-HER3 and osimertinib groups themselves exhibited significant tumor size reduction compared with vehicle, but the benefit of the combination therapy was higher and was reached earlier, showing significant tumor volume reduction vs. osimertinib monotherapy at 8-days post-treatment (Fig. 4B). Here, ERBB3 is linked to neoplasm.